Das metabolische Syndrom

H. Mönig

doi:10.1055/s-0033-1360056

Lege artis - Das Magazin zur ärztlichen Weiterbildung, Table of Contents

Aktuelle Ernährungsmedizin 2014; 39(01): 60-77
DOI: 10.1055/s-0033-1360056

CME-Weiterbildung

Das metabolische Syndrom

Metabolic Syndrome

H. Mönig

Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel

› Author Affiliations

Abstract

Zusammenfassung

Der Begriff „metabolisches Syndrom“ (MetS) kennzeichnet eine Risikokonstellation für die Entwicklung kardiovaskulärer Erkrankungen und eines Typ-2-Diabetes mellitus. Bestandteil des Syndroms sind ein erhöhter Taillenumfang als Ausdruck einer zentralen (abdominalen) Adipositas, eine Glukosestoffwechselstörung, eine atherogene Dyslipidämie sowie eine essenzielle arterielle Hypertonie. Die Prävalenz des metabolischen Syndroms nimmt weltweit zu und erreicht in Deutschland in der Gruppe der 50 – 70-Jährigen ca. 40 %. Wesentlicher Therapie- und Präventionsansatz ist die Lebensstilintervention mit dem Ziel, die zentrale Adipositas zu reduzieren; darüber hinaus ist in den meisten Fällen eine Pharmakotherapie der einzelnen Komponenten des Syndroms erforderlich.

Abstract

The term “metabolic syndrome” refers to a cluster of factors that increase the risk of cardiovascular diseases and type 2 diabetes mellitus. The syndrome comprises central (abdominal) obesity, dysregulated glucose homeostasis, atherogenic dyslipidemia, and elevation of arterial blood pressure. Prevalence of the metabolic syndrome increases worldwide and approximates 40 % in the age group 50 – 70 years in Germany. Lifestyle intervention is the key measure in reducing central obesity. Pharmacological treatment of the single components the syndrome is often mandatory.

Schlüsselwörter

metabolisches Syndrom - Adipositas - Diabetes mellitus - Hypertonus - Dyslipidämie - Ernährung - Lebensstil

Keywords

metabolic syndrome - obesity - diabetes mellitus - hypertension - dyslipidemia - nutrition - life style

Full Text

References

Literatur
1 Nabipour I, Amiri M, Imami SR et al. The metabolic syndrome and nonfatal ischemic heart disease; a population-based study. Int J Cardiol 2007; 118: 48-53
2 Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2009; 4: 113-119
3 Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904
4 Hanefeld M, Leonhardt W. Das metabolische Syndrom. Dt Gesundheitswesen 1981; 36: 545-551
5 Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607
6 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
7 Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
8 Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059-1062
9 Alberti KG, Eckel RH, Grundy SM et al. International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
10 Kassi E, Pervanidou P, Kaltsas G et al. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48
11 Zimmet P, Alberti KG, Kaufman F et al. IDF Consensus Group: The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes 2007; 8: 299-306
12 Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Report 2009; 13: 1-7
13 Moebus S, Hanisch J, Neuhaeuser M et al. Assessing the prevalence of the Metabolic Syndrome according to NCEP ATP III in Germany: feasibility and quality aspects of a two step approach in 1550 randomly selected primary health care practices. GMS Ger Med Sci 2006; 4
14 Moebus S, Hanisch J, Bramlage P et al. Regional differences in the prevalence of the metabolic syndrome in primary care practices in Germany. Dtsch Arztebl Int 2008; 105: 207-213
15 Wirth A, Hauner H. Das Metabolische Syndrom. 1.. Aufl. München: Urban & Vogel; 2007
16 Mente A, Yusuf S, Islam S et al. INTERHEART Investigators: Metabolic syndrome and risk of acute myocardial infarction a casecontrol study of 26,903 subjects from 52 countries. J Am Coll Cardiol 2010; 55: 2390-2398
17 Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-1132
18 Blake GJ, Otvos JD, Rifai N et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 1930-1937
19 Blüher M, Hamann A. Adipositas und metabolisches Syndrom. Diabetologie 2013; 8: R31-R46
20 Kahn R, Buse J, Ferrannini E et al. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304
21 Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
22 Hunt KJ, Resendez RG, Williams K et al. Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251-1257
23 Emerging Risk Factors Collaboration. Wormser D, Kaptoge S, Di Angelantonio E et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; 377: 1085-1095
24 Curti ML, Jacob P, Borges MC et al. Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J Obes 2011;
25 Farooqi IS. The severely obese patient – a genetic work-up. Nat Clin Pract Endocrinol Metab 2006; 2: 172-177
26 Solinas G, Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J 2010; 24: 2596-2611
27 Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316: 889-894
28 Frayling TM, Ong K. Piecing together the FTO jigsaw. Genome Biol 2011; 12: 104
29 Phillips CM. Nutrigenetics and metabolic disease: current status and implications for personalised nutrition. Nutrients 2013; 5: 32-57
30 Sanghez V, Razzoli M, Carobbio S et al. Psychosocial stress induces hyperphagia and exacerbates diet-induced insulin resistance and the manifestations of the Metabolic Syndrome. Psychoneuroendocrinology 2013; Sep 2. pii: S0306-4530(13)00287-4. [Epub ahead of print]
31 Chaput JP, McNeil J, Després JP et al. Seven to eight hours of sleep a night is associated with a lower prevalence of the metabolic syndrome and reduced overall cardiometabolic risk in adults. PLoS One 2013; 8 e72832.do.pone.0072832i: 10.1371/journal
32 Ho CH, Yu HJ, Wang CY et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One 2013; Sep 12; 8(9): e74173.:
33 Akira Tsujimura A. The relationship between testosterone deficiency and men’s health. World J Mens Health 2013; 31: 126-135
34 Dunaif A, Fauser B. Renaming PCOS – A Two State Solution. J Clin Endocrinol Metab 2013; Sep 5. [Epub ahead of print]
35 Guasch A, Bulló M, Rabassa A et al. Plasma vitamin D and parathormone are associated with obesity and atherogenic dyslipidemia: a cross-sectional study. Cardiovasc Diabetol 2012; 11: 149
36 Peters A, Langemann D. Build-ups in the supply chain of the brain: on the neuroenergetic cause of obesity and type 2 diabetes mellitus. Front Neuroenergetics 1:2.
37 Kahn SE, Prigeon RL, Schwartz RS et al. Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 2001; 131: 354S-360S
38 Cornier MA, Dabelea D, Hernandez TL et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822
39 Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010; (Epub 2010 Aug 5)
40 Diamond F. The Endocrine Function of Adipose Tissue. GGH; 2002. 18. Im Internet: http://www.gghjournal.com/volume18/18-2/articles/diamond/diamond.htm (Stand: 30.10.2013)
41 Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010; 16: 1896-1901
42 Okamoto Y, Kihara S, Funahashi T et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267-278
43 Kim JH, Kim SH, Im JA et al. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 2010; 67: 67-71
44 Standeven KF, Hess K, Carter AM et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond) 2011; 35: 1031-1040
45 Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in dietinduced obese mice. Diabetes 2009; 58: 250-259
46 Garg A. The role of body fat distribution in insulin resistance. In: Reaven GM, Laws A, ed. Insulin Resistance; The Metabolic Syndrome X. 1.. Aufl. Totowa, NJ, USA: Humana Press; 1999: 83-96
47 Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab 2004; 89: 4206-4210
48 Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes 2013; (Epub 2013 Apr 4)
49 Gealekman O, Guseva N, Hartigan C et al. Depot-specific differences and insufficient subcutaneous adipose tissue angiogenesis in human obesity. Circulation 2011; 123: 186-194
50 Jolly US, Soliman A, McKenzie C et al. Intra-thoracic fat volume is associated with myocardial infarction in patients with metabolic syndrome. J Cardiovasc Magn Reson 2013; 15: 77
51 Klöting N, Stumvoll M, Blüher M. Biologie des viszeralen Fetts. Internist (Berl) 2007; 48: 126-133
52 Abate N, Garg A, Peshock RM et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995; 96: 88-98
53 Snijder MB, Visser M, Dekker JM et al. Health ABC Study. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia 2005; 48: 301-308
54 Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol 2006; 151: 122-134
55 Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr 2010; 140: 648-652
56 Begum G, Davies A, Stevens A et al. Maternal undernutrition programs tissue-specific epigenetic changes in the glucocorticoid receptor in adult offspring. Endocrinology 2013; Sep 24. [Epub ahead of print]
57 Brenseke B, Prater MR, Bahamonde J et al. Current thoughts on maternal nutrition and fetal programming of the metabolic syndrome. J Pregnancy 2013;
58 Saggese G, Fanos M, Simi F. SGA children: auxological and metabolic outcomes – the role of GH treatment. J Matern Fetal Neonatal Med 2013; 26 (Suppl. 02) 64-67
59 McClure CK, Catov JM, Ness R et al. Associations between gestational weight gain and BMI, abdominal adiposity, and traditional measures of cardiometabolic risk in mothers 8 y postpartum. Am J Clin Nutr 2013; Sep 18. [Epub ahead of print]
60 Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9: 211-224
61 Kumar PA, Chitra PS, Reddy GB. Metabolic syndrome and associated chronic kidney diseases: Nutritional interventions. Rev Endocr Metab Disord 2013; 14: 273-286
62 Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; Oct 3;347: f5680.
63 Schneider HJ, Friedrich N, Klotsche J et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab 2010; 95: 1777-1785
64 Hauner H, Buchholz G, Hamann A et al. Evidenzbasierte Leitlinie-Prävention und Therapie der Adipositas, Version 2007. Herausgeber: Deutsche Adipositas-Gesellschaft, Deutsche Diabetes-Gesellschaft, Deutsche Gesellschaft für Ernährung, Deutsche Gesellschaft für Ernährungsmedizin. Im Internet: http://www.dge.de/pdf/ll/Adipositas-Leitlinie-2007.pdf (Stand: 20.10.2013)
65 Tuomilehto J, Lindström J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
66 Salas-Salvado J, Martinez-Gonzalez MA, Bullo M et al. The role of diet in the prevention of type 2 diabetes. Nutr Metab Cardiovasc Dis 2011; 21 (Suppl. 02) B32-48
67 Campos Pastor MM, Serrano Pardo MD, Fernández Soto ML et al. Impact of a “school-based” nutrition intervention on anthropometric parameters and the metabolic syndrome in Spanish adolescents. Ann Nutr Metab 2012; 61: 281-288
68 The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154
69 Rumawas ME, Meigs JB, Dwyer JT et al. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits and incidence in the Framingham Offspring Cohort. Am J Clin Nutr 2009; 90: 1608-1614
70 Estruch R, Ros E, Salas-Salvadó J et al. PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-1290
71 Kastorini CM, Milionis HJ, Esposito K et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011; 57: 1299-1313
72 Estruch R, Martínez-González MA, Corella D et al. PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006; 145: 1-11
73 Salas-Salvadó J, Bulló M, Babio N et al. PREDIMED Study Investigators. Reduction in the incidence of type 2 diabetes with the mediterranean diet. Diabetes Care 2011; 34: 14-19
74 Ibarrola-Jurado N, Bulló M, Guasch-Ferré M et al. PREDIMED Study Investigators. Cross-sectional assessment of nut consumption and obesity, metabolic syndrome and other cardiometabolic risk factors: the PREDIMED study. PLoS One 2013; 8 e57367. (Epub 2013 Feb 27)
75 Ros E, Mataix J. Fatty acid composition of nuts – implications for cardiovascular health. Br J Nutr 2006; 96 (Suppl. 02) S29-35
76 Segura R, Javierre C, Lizarraga MA et al. Other relevant components of nuts: phytosterols, folate and minerals. Br J Nutr 2006; 96 (Suppl. 02) S36-44
77 Blomhoff R, Carlsen MH, Andersen LF et al. Health benefits of nuts: potential role of antioxidants. Br J Nutr 2006; 96 (Suppl. 02) S52-60
78 Chen CY, Blumberg JB. Phytochemical composition of nuts. Asia Pac J Clin Nutr 2008; 17 (Suppl. 01) 329-332
79 European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G et al. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818
80 Hikmat F, Appel LJ. Effects of the DASH diet on blood pressure in patients with and without metabolic syndrome: results from the DASH trial. J Hum Hypertens 2013; Sep 26. [Epub ahead of print]
81 Brönstrup A, Hauner H. Kohlenhydratzufuhr und Prävention des Metabolischen Syndroms. In: Deutsche Gesellschaft für Ernährung e. V., Hrsg. Evidenzbasierte Leitlinie Kohlenhydratzufuhr und Prävention ausgewählter ernährungsmitbedingter Krankheiten, Version 2011. Evid Based Complement Alternat Med 2013; Stand: 13.10.2013; Im Internet: http://www.dge.de/pdf/ws/ll-kh/DGE-Leitlinie-KH-ohne-Anhang_Tabellen.pdf (Epub 2013 Feb 27)
82 Kim JJ, Tan Y, Xiao L et al. Green tea polyphenol epigallocatechin-3-gallate enhance glycogen synthesis and inhibit lipogenesis in hepatocytes. Biomed Res Int 2013; (Epub 2013 Aug 27)
83 Schloms L, Smith C, Storbeck KH et al. Rooibos influences glucocorticoid levels and steroid ratios in vivo and in vitro: A natural approach in the management of stress and metabolic disorders?. Mol Nutr Food Res 2013; Sep 11. [Epub ahead of print]
84 Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes. Im Internet: http://www.deutschediabetesgesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/NVL-DM2-Ther-lang_Endversion_270813.pdf (Stand: 13.10.2013)
85 Katsiki N, Athyros VG, Karagiannis A et al. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2013; Sep 12. [Epub ahead of print]
86 Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-219
87 Watts GF, Ooi EM, Chan DC. Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol 2013; Sep 24. [Epub ahead of print]
88 Rajesh Tota-Maharaja R, Andrew P, Defilippisa AP et al. A practical approach to the metabolic syndrome: review of current concepts and management. Curr Opin Cardiol 2010; 25: 502-512
89 Iannelli A, Anty R, Schneck AS et al. Evolution of low-grade systemic inflammation, insulin resistance, anthropometrics, resting energy expenditure and metabolic syndrome after bariatric surgery: A comparative study between gastric bypass and sleeve gastrectomy. J Visc Surg 2013; 150: 269-275
90 Siejka A, Jankiewicz-Wika J, Kołomecki K et al. Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine 2013; Sep 5. pii: S1043-4666(13)00642-X. [Epub ahead of print]
91 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553